Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD
Primary endpoint met, with TSND-201 demonstrating statistically significant placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p = 0.011) TSND-201 demonstrated... Read more.
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY, March 31,... Read more.
DeFi Technologies Inc. Announces Record 2024 Financial Results: Adjusted Revenues of C$204.4 million (US$144.8 million), Adjusted EBITDA of $116.1 million (US$80.4 million) and Adjusted Net Income of C$115.07 million (US$84 million) and Notable Strategic Developments
Adjusted Revenues, Adjusted EBITDA and Adjusted Net Income: DeFi Technologies recorded Adjusted Revenues of C$42.6 million (approximately US$31.1 million) and C$204.4... Read more.
Calamos Announces Cap Ranges of Principal Protected Bitcoin ETFs April Series on the Heels of a Successful Inaugural Launch
METRO CHICAGO, Ill., March 31, 2025 /PRNewswire/ — John Koudounis, President and CEO of Calamos, announced the planned April launch of the three new ETFs in... Read more.
BTQ Technologies Chief Quantum Officer Dr. Gavin Brennen to Join Fireside Chat on Quantum Funding and Policy at Quantum Industry Day in Sydney
BTQ’s Dr. Gavin Brennen to Speak at Quantum Industry Day in Sydney: BTQ Technologies’ Chief Quantum Officer, Dr. Gavin Brennen, will join a fireside... Read more.
TriPost Partners with Invesco Real Estate Income Trust Inc. to Acquire Minority Equity Stake in Class-A Student Housing Community in Arizona
TriPost’s Asset Solutions Strategy Completes Inaugural Secondary Market Transaction, Leveraging its Deep Track Record of Investing in Real Estate Operators... Read more.
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for... Read more.
Sekur Private Data Ltd. Announces Closing of Last Tranche of its Non-Brokered Private Placement Management and Insiders Participation at 30%
MIAMI and TORONTO, March 31, 2025 /PRNewswire/ — Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) (“Sekur” or the “Company”),... Read more.
Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic
Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug... Read more.
Sapiens Life Platform Selected by a Leading U.S. Insurer
Sapiens’ solutions accelerate insurer’s seamless, data-driven digital transformation ROCHELLE PARK, N.J., March 31, 2025 /PRNewswire/ — Sapiens... Read more.